

Frédéric Collet is reappointed Chairman of Leem

Putting pharmaceuticals back at the heart of strategic priorities



On 16 June, the Board of Directors of Leem (the French Association of Pharmaceutical Companies) reappointed Frédéric Collet as its chairman for a further term of two years. He has been Chairman of Leem since 9 July 2019.

This new term of office for Frédéric Collet begins during an exceptional period that demands progressive and prudent management of our emergence from an unprecedented health crisis and is seeing increasingly rapid development of innovative new therapies. When his appointment comes to an end two years from now, it will coincide with a major event in the form of the 2022 French presidential election, when health will be central to the debate over the nation's future. It would be an understatement to say that the forthcoming two years will be decisive in meeting new challenges and delivering the necessary healthcare transformations.

"I'm in no doubt that these exceptional circumstances are accelerating the urgency of delivering transformational change", says Leem Chairman Frédéric Collet. "Throughout the pandemic, every healthcare professional has demonstrated their agility and capability in responding to a series of emergencies. I believe that it's important to maintain this momentum to meet the expectations of society and the needs of patients. Our pharmaceutical companies are key players in the healthcare sector as a whole. As such, they make a decisive contribution to the dynamism of the French healthcare sector and must be allowed to provide input to the collective effort needed to rebuild our national healthcare system".

Frédéric Collet embarks on his period of reappointment with a clear roadmap based on four priorities:

- Rethinking the future of our healthcare system and fundamentally transforming the associated pharmaceuticals policy
- Enabling universal early-stage patient access to major therapeutic innovations and introducing a new policy of horizon scanning

- Continuing to develop new technologies for patients and healthcare systems, including telemedicine, data development and mobile apps
- Boosting the appeal of France in terms of inward investment in research and clinical trials, and ensuring that French manufacturing facilities can be competitive and capable of winning the strategically important production opportunities of tomorrow.

Now, more than ever, he wants to be able to rely on a strong and coherent collective effort to carry forward this ambitious programme through what are exceptional times.

Frédéric Collet

The Chairman of Novartis has been a director of Leem since 2013. He was secretary to the Board of Leem between September 2018 and June 2019. During this period, he was also the lead representative for European pharmaceutical companies and Chairman of the Leem Cancer Committee.

Frédéric Collet is 56 and a graduate of the Paris Institute of Political Studies (IEP) and the University of Paris II Panthéon-Assas. He began his career in the cosmetics industry with the Henkel Group in France and Great Britain before joining the Novartis Group and its ophthalmic medical devices business as CEO of Ciba Vision in 2005. In 2009, he moved to generic and biosimilar pharmaceuticals manufacturer Sandoz France as its President. In 2015, he was appointed General Manager of Novartis Oncology France, and was closely involved in developing this strategically important new division of the Group. He also successfully integrated the haematology, oncology and rare diseases activities of GSK into Novartis. Frédéric Collet has been Group Country President of Novartis France since April 2017. He chairs the Executive Committee whose responsibilities span the business activities of Novartis Pharma and Oncology, Sandoz and the Novartis Biotechnology Centre in Huningue. He is also the General Manager of Novartis Oncology in France, a director of Novartis subsidiary AAA (Advanced Accelerator Applications) and President of CellforCure.

LEEM IN BRIEF

As a professional body representing pharmaceutical companies operating in France, Leem is central to the major health challenges of today. Against a background of unprecedented scientific and industrial change, it works actively with its 270 members and their 99,000 employees to take French pharmaceutical research and production excellence to a new level, at the same time as promoting innovation and progress for the benefit of patients. As a promoter of responsible behaviour in the health system, Leem contributes to building trust in pharmaceutical products through high-quality initiatives that put safety and transparency first.

Leem press contacts:

Stéphanie Bou - Tel.: +33 (0)1 45 03 88 38 - e-mail: sbou@leem.org

Virginie Pautre – Tel.: 01 45 03 88 87 - e-mail: vpautre@leem.org

Elisa Mahdadi - emahdadi@leem.org